Value-based contracts (VBC) are increasingly considered by companies for many types of therapies. Some companies are suggesting that VBC will become the default for them across their portfolio.
Josie Godfrey, Malcom Qualie, Heather McDonald, John Pincher
FREE | REGISTER NOW
COVID-19 has had a huge impact on how we all think and act. Our working environments may look very different now to the way they did pre-pandemic, and not all the changes have been negative.
Andrés López Castaño, Tricia Lucas-Clarke, Noor Shaker, Sandra Van de Cauter, Marsha N. Ganthier
FREE | VIEW NOW
Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to market.
Kate Shaw, Founder & CEO, Innovative Trials; Jane Thurston, Senior Patient Recruitment Lead, Parexel; Whitney Taynton, Business Unit Head, Innovative Trials
FREE WEBINAR | VIEW NOW
Having traditionally found itself near the bottom of digital adoption league tables, the scale and maturity of customer engagement practices within the pharmaceutical industry, accelerated by the COVID-19 pandemic, are now building at considerable pace.
Simon Grime: Digital Engagement Director, Wilmington Healthcare Tina White: Principal Clinical Consultant – Commissioning, Wilmington Healthcare Julian Snape: Commercial Optimisation Director, Wilmington Healthcare
FREE | VIEW NOW
We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient recruitment.
Kate Shaw - Founder/CEO, Innovative Trials
FREE | VIEW NOW
Following a forest fire, the natural world recovers according to predictable patterns, in a process known as ‘ecological succession’. After the global conflagration of COVID-19, what will the equivalent patterns look like for health?
Langland, a Publicis Health Company
FREE | VIEW NOW
We often hear patients report a lack of ‘connection’ with their physician, and where lifestyle plays a role in the development of a disease, such as obesity or type 2 diabetes, patients may even feel the doctor blames them for their condition.
Andrew McConaghie, Group Editor
FREE | VIEW NOW
As medicines access evolves and pharmaceutical companies take an increasingly nuanced approach to it, it’s ever-more important to focus on particular aspects of this area and investigate whether firms are operating optimally.
Dominic Tyer, Editorial director
FREE | VIEW NOW
The healthcare landscape is rapidly changing as it responds to a multitude of well-known issues. Coupled with emerging digital technologies, these drivers are shaping the industry, moving it towards a more sophisticated, outcomes-driven model that demands a new approach.
Dominic Tyer, Editorial director
FREE | VIEW NOW
With traditional media moving online, and the era of social media driving stories through the ethernet, never has a ‘story’ been more impactful.
Dominic Tyer, Editorial director
FREE | VIEW NOW
‘The Truth about Doctors’ the first study in the series, aims to get to the heart of the human under the white coat to better understand what motivates doctors and how we can improve the way we communicate to them.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Patient insights aren’t just a ‘nice to have’: they are essential to understand the space where Pharma’s drugs ‘live’.
Dominic Tyer, Editorial director
FREE | VIEW NOW
When new products approach the market the level of demand for them is often exaggerated.
Dominic Tyer, Editorial director
FREE | VIEW NOW
To successfully develop and launch an asset it’s crucial to identify and define the commercial value early in the process.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Everyone in pharma is talking about patient centricity, but how is the drive received ‘on the ground’ among patients who are its focus? How is it unfolding and how far is it being implemented? Do patients even notice it is happening?
Dominic Tyer, Editorial director
FREE | VIEW NOW
Involving public affairs early during the development and commercialisation process of a new asset is critical to success when demonstrating value to payers and policy makers.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Most life sciences companies know they need to move their multichannel marketing forward, but that requires managing a greater volume of tactics that need to be developed, approved, implemented, and measured.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Measuring campaign success is key for pharma and the rise of multichannel campaigns has brought with it an increase in spending on commercial analytic solutions, which help users identify opportunities for improvements.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Traditional models of cognitive behaviour remain meaningful, but they can fail to deliver strong links between ‘smart’, cognitive-based factors of judgement and the decision-making associated with actual behaviour change.
Dominic Tyer, Editorial director
FREE | VIEW NOW
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...